Hyderabad-Based Pharma Company, Sigachi Industries Achieves Key R&D Milestone in Cystic Fibrosis APIs
DSIJ Intelligence-1Categories: Mindshare, Trending
The production of these specific APIs involves intricate multi-step synthesis and specialised chemical reactions, creating high technological barriers to entry that limit market competition.
Sigachi Industries Ltd has reached a significant R&D milestone by successfully developing a complex combination of Active Pharmaceutical Ingredients (APIs) for Cystic Fibrosis, including Vanzacaftor, Tezacaftor, and Deutivacaftor. This advancement signals a strategic pivot toward high-value specialty APIs, targeting a global therapeutics market valued at over USD 10 billion. By entering this niche segment, the company aims to meet the rising demand for next-generation modulator therapies used in treating rare and chronic respiratory conditions.
The production of these specific APIs involves intricate multi-step synthesis and specialised chemical reactions, creating high technological barriers to entry that limit market competition. Sigachi is currently exploring strategic collaborations with formulation innovators for research and future commercial supply. With innovator patent protections for components like Vanzacaftor extending until 2039, the company is positioning itself for long-term commercial stability and sustained participation in the global cystic fibrosis supply chain.
Financially, this development is expected to become a major growth driver for the company starting in the fourth quarter of FY 2026–27. Internal assesSMEnts estimate an annual revenue potential of approximately Rs 250 crore from this portfolio, contingent upon successful partnerships and market progression. This move reinforces Sigachi’s manufacturing capabilities in complex chemistries while aligning its portfolio with high-margin, innovation-led therapeutic segments.
About the Company
Sigachi Industries Limited is a global pharmaceutical leader with over 36 years of experience, specialising in the development of APIs, excipients, and nutrition solutions. Operating through five manufacturing facilities across India and subsidiaries in the UAE and the USA, the company serves clients in more than 65 countries with a strong commitment to R&D and regulatory excellence. By leveraging cutting-edge technology and customer-centric innovation, Sigachi continues to provide high-value healthcare and nutraceutical ingredients to partners worldwide.
The company has a market cap of over Rs 900 crore with promoters holding 39.70 per cent stake in the company. The shares of the company have a 52-week high of Rs 59.50 per share and a 52-week low of Rs 23.46 per share. As of December 2025, FIIs have increased their stake to 3.33 per cent compared to September 2025.
Disclaimer: The article is for informational purposes only and not investment advice.